These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 10946142

  • 21. Immunological correlates of vaccination and infection for equine herpesvirus 1.
    Goodman LB, Wimer C, Dubovi EJ, Gold C, Wagner B.
    Clin Vaccine Immunol; 2012 Feb; 19(2):235-41. PubMed ID: 22205656
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Use of the meridian test for the detection of equine herpesvirus type 1 infection in horses with decreased performance.
    Chvala S, Nowotny N, Kotzab E, Cain M, van den Hoven R.
    J Am Vet Med Assoc; 2004 Aug 15; 225(4):554-9. PubMed ID: 15344363
    [Abstract] [Full Text] [Related]

  • 25. Antibody reactions of horses against various domains of the EHV-1 receptor-binding protein gD1.
    Schramm A, Ackermann M, Eichwald C, Aguilar C, Fraefel C, Lechmann J.
    PLoS One; 2024 Aug 15; 19(7):e0301987. PubMed ID: 38995916
    [Abstract] [Full Text] [Related]

  • 26. Comparison of protective efficacies between intranasal and intramuscular vaccination of horses with a modified live equine herpesvirus type-1 vaccine.
    Bannai H, Nemoto M, Tsujimura K, Yamanaka T, Kokado H, Kondo T, Matsumura T.
    Vet Microbiol; 2018 Aug 15; 222():18-24. PubMed ID: 30080668
    [Abstract] [Full Text] [Related]

  • 27. Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)--epidemiology, disease and immunoprophylaxis: a brief review.
    Patel JR, Heldens J.
    Vet J; 2005 Jul 15; 170(1):14-23. PubMed ID: 15993786
    [Abstract] [Full Text] [Related]

  • 28. Intranasal IgG4/7 antibody responses protect horses against equid herpesvirus-1 (EHV-1) infection including nasal virus shedding and cell-associated viremia.
    Perkins G, Babasyan S, Stout AE, Freer H, Rollins A, Wimer CL, Wagner B.
    Virology; 2019 May 15; 531():219-232. PubMed ID: 30928700
    [Abstract] [Full Text] [Related]

  • 29. Development of a peptide ELISA for discrimination between serological responses to equine herpesvirus type 1 and 4.
    Lang A, de Vries M, Feineis S, Müller E, Osterrieder N, Damiani AM.
    J Virol Methods; 2013 Nov 15; 193(2):667-73. PubMed ID: 23928223
    [Abstract] [Full Text] [Related]

  • 30. An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease.
    Schnabel CL, Babasyan S, Rollins A, Freer H, Wimer CL, Perkins GA, Raza F, Osterrieder N, Wagner B.
    J Virol; 2019 Nov 15; 93(22):. PubMed ID: 31462575
    [Abstract] [Full Text] [Related]

  • 31. Protective effects of equine herpesvirus-1 (EHV-1) glycoprotein B in a murine model of EHV-1-induced abortion.
    Kukreja A, Walker C, Fitzmaurice T, Awan A, Love DN, Whalley JM, Field HJ.
    Vet Microbiol; 1998 Aug 15; 62(4):303-11. PubMed ID: 9791876
    [Abstract] [Full Text] [Related]

  • 32. Neonatal Immunization with a Single IL-4/Antigen Dose Induces Increased Antibody Responses after Challenge Infection with Equine Herpesvirus Type 1 (EHV-1) at Weanling Age.
    Wagner B, Perkins G, Babasyan S, Freer H, Keggan A, Goodman LB, Glaser A, Torsteinsdóttir S, Svansson V, Björnsdóttir S.
    PLoS One; 2017 Aug 15; 12(1):e0169072. PubMed ID: 28045974
    [Abstract] [Full Text] [Related]

  • 33. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).
    Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzger SM, Holland R, Osterrieder N.
    Vaccine; 2006 Apr 24; 24(17):3636-45. PubMed ID: 16513225
    [Abstract] [Full Text] [Related]

  • 34. Successful control of winter pyrexias caused by equine herpesvirus type 1 in Japanese training centers by achieving high vaccination coverage.
    Bannai H, Mae N, Ode H, Nemoto M, Tsujimura K, Yamanaka T, Kondo T, Matsumura T.
    Clin Vaccine Immunol; 2014 Aug 24; 21(8):1070-6. PubMed ID: 24872513
    [Abstract] [Full Text] [Related]

  • 35. A prime-boost immunization strategy with DNA and recombinant baculovirus-expressed protein enhances protective immunogenicity of glycoprotein D of equine herpesvirus 1 in naïve and infection-primed mice.
    Ruitenberg KM, Walker C, Love DN, Wellington JE, Whalley JM.
    Vaccine; 2000 Jan 31; 18(14):1367-73. PubMed ID: 10618534
    [Abstract] [Full Text] [Related]

  • 36. Immune responses to commercial equine vaccines against equine herpesvirus-1, equine influenza virus, eastern equine encephalomyelitis, and tetanus.
    Holmes MA, Townsend HG, Kohler AK, Hussey S, Breathnach C, Barnett C, Holland R, Lunn DP.
    Vet Immunol Immunopathol; 2006 May 15; 111(1-2):67-80. PubMed ID: 16476488
    [Abstract] [Full Text] [Related]

  • 37. Pre-infection frequencies of equine herpesvirus-1 specific, cytotoxic T lymphocytes correlate with protection against abortion following experimental infection of pregnant mares.
    Kydd JH, Wattrang E, Hannant D.
    Vet Immunol Immunopathol; 2003 Dec 15; 96(3-4):207-17. PubMed ID: 14592733
    [Abstract] [Full Text] [Related]

  • 38. Diagnosis and sero-epizootiology of equine herpesvirus type 1 and type 4 infections in Japan using a type-specific ELISA.
    Yasunaga S, Maeda K, Matsumura T, Kai K, Iwata H, Inoue T.
    J Vet Med Sci; 1998 Oct 15; 60(10):1133-7. PubMed ID: 9819768
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Duration of immunity induced by an adjuvanted and inactivated equine influenza, tetanus and equine herpesvirus 1 and 4 combination vaccine.
    Heldens JG, Kersten AJ, Weststrate MW, van den Hoven R.
    Vet Q; 2001 Nov 15; 23(4):210-7. PubMed ID: 11765243
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.